{"title":"1999年至2024年HIV-1耐药少数变异的文献计量学分析","authors":"Chang Yan, Fengting Yu, Mengying Li, Xiaojie Yang, Rui Sun, Xuelei Liang, Xiaojie Lao, Hanxi Zhang, Wenhao Lv, Ying Hu, Yuan Lai, Yi Ding, Fujie Zhang","doi":"10.1186/s12981-025-00739-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The rapid initiation of antiretroviral therapy has become an international trend, necessitating lifelong medication for all HIV patients. Sanger sequencing, as the gold standard for clinically detecting HIV drug resistance, often fails to detect mutations comprising less than 20% of the total viral population. With the advancement of detection technologies, HIV-1 drug-resistant minority variants have garnered increasing attention. Few studies have analyzed the hotspots and trends in this field, which bibliometrics can effectively address.</p><p><strong>Methods: </strong>Publications related to HIV-1 DRMinVs from 1999 to 2024 were searched on the Web of Science Core Collection database. Visual knowledge maps and bibliometric analyses were generated using VOSviewer and Bibliometrix.</p><p><strong>Results: </strong>In total, 289 publications concerning HIV-1 drug-resistant minority variants were identified from 1999 to 2024, demonstrating a steady increase in publication output over the years. Although developed countries, led by the United States, are the main contributors, 9.57% and 2.48% of the research from the top five publishing countries focus on populations in Africa and other developing countries, respectively. Most contributing institutions are universities and public health organizations, with the University of Washington having the highest publication output. The Journal of Antimicrobial Chemotherapy holds the highest prominence among journals in this domain. The main hotspots include \"drug classes,\" \"drug resistance surveillance,\" \"mother-to-child transmission,\" \"treatment outcomes,\" and \"targets of HIV-1 drug resistance testing,\" And we found several noteworthy shifts in research trends in HIV-1 drug-resistant minority variants studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.</p><p><strong>Conclusions: </strong>This is the first bibliometric analysis of publications related to HIV-1 DRMinVs from 1999 to 2024. We analyzed the key research contributions across countries, institutions and journals. Based on keyword co-occurrence and cluster analysis, we identified several noteworthy shifts in research trends in HIV-1 DRMinVs studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"47"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984210/pdf/","citationCount":"0","resultStr":"{\"title\":\"A bibliometric analysis of HIV-1 drug-resistant minority variants from 1999 to 2024.\",\"authors\":\"Chang Yan, Fengting Yu, Mengying Li, Xiaojie Yang, Rui Sun, Xuelei Liang, Xiaojie Lao, Hanxi Zhang, Wenhao Lv, Ying Hu, Yuan Lai, Yi Ding, Fujie Zhang\",\"doi\":\"10.1186/s12981-025-00739-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The rapid initiation of antiretroviral therapy has become an international trend, necessitating lifelong medication for all HIV patients. Sanger sequencing, as the gold standard for clinically detecting HIV drug resistance, often fails to detect mutations comprising less than 20% of the total viral population. With the advancement of detection technologies, HIV-1 drug-resistant minority variants have garnered increasing attention. Few studies have analyzed the hotspots and trends in this field, which bibliometrics can effectively address.</p><p><strong>Methods: </strong>Publications related to HIV-1 DRMinVs from 1999 to 2024 were searched on the Web of Science Core Collection database. Visual knowledge maps and bibliometric analyses were generated using VOSviewer and Bibliometrix.</p><p><strong>Results: </strong>In total, 289 publications concerning HIV-1 drug-resistant minority variants were identified from 1999 to 2024, demonstrating a steady increase in publication output over the years. Although developed countries, led by the United States, are the main contributors, 9.57% and 2.48% of the research from the top five publishing countries focus on populations in Africa and other developing countries, respectively. Most contributing institutions are universities and public health organizations, with the University of Washington having the highest publication output. The Journal of Antimicrobial Chemotherapy holds the highest prominence among journals in this domain. The main hotspots include \\\"drug classes,\\\" \\\"drug resistance surveillance,\\\" \\\"mother-to-child transmission,\\\" \\\"treatment outcomes,\\\" and \\\"targets of HIV-1 drug resistance testing,\\\" And we found several noteworthy shifts in research trends in HIV-1 drug-resistant minority variants studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.</p><p><strong>Conclusions: </strong>This is the first bibliometric analysis of publications related to HIV-1 DRMinVs from 1999 to 2024. We analyzed the key research contributions across countries, institutions and journals. Based on keyword co-occurrence and cluster analysis, we identified several noteworthy shifts in research trends in HIV-1 DRMinVs studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.</p>\",\"PeriodicalId\":7503,\"journal\":{\"name\":\"AIDS Research and Therapy\",\"volume\":\"22 1\",\"pages\":\"47\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984210/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS Research and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12981-025-00739-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00739-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:快速开始抗逆转录病毒治疗已成为一种国际趋势,所有艾滋病毒患者都需要终身用药。Sanger测序作为临床检测HIV耐药性的金标准,往往无法检测到占病毒总数不到20%的突变。随着检测技术的进步,HIV-1耐药少数变异引起了越来越多的关注。很少有研究分析了这一领域的热点和趋势,而文献计量学可以有效地解决这一问题。方法:检索Web of Science Core Collection数据库1999 ~ 2024年与HIV-1 DRMinVs相关的出版物。使用VOSviewer和Bibliometrix生成可视化知识图谱和文献计量学分析。结果:从1999年到2024年,共鉴定出289篇关于HIV-1耐药少数变异的出版物,显示出多年来出版物产量的稳步增长。虽然以美国为首的发达国家是主要贡献者,但前五大出版国的研究中,分别有9.57%和2.48%的研究集中在非洲和其他发展中国家的人口上。发表论文最多的机构是大学和公共卫生组织,其中华盛顿大学的论文发表量最高。抗菌化疗杂志在这一领域的期刊中占有最高的地位。主要热点包括“药物类别”、“耐药监测”、“母婴传播”、“治疗结果”和“HIV-1耐药检测靶点”。我们发现HIV-1耐药少数变异研究的研究趋势发生了一些值得注意的变化,包括耐药检测技术、主要研究人群和药物类别的变化。结论:这是对1999年至2024年HIV-1 drminv相关出版物的首次文献计量学分析。我们分析了不同国家、机构和期刊的主要研究贡献。基于关键词共现和聚类分析,我们确定了HIV-1 DRMinVs研究趋势的几个值得注意的变化,包括耐药测试技术、主要研究人群和药物类别的变化。
A bibliometric analysis of HIV-1 drug-resistant minority variants from 1999 to 2024.
Background: The rapid initiation of antiretroviral therapy has become an international trend, necessitating lifelong medication for all HIV patients. Sanger sequencing, as the gold standard for clinically detecting HIV drug resistance, often fails to detect mutations comprising less than 20% of the total viral population. With the advancement of detection technologies, HIV-1 drug-resistant minority variants have garnered increasing attention. Few studies have analyzed the hotspots and trends in this field, which bibliometrics can effectively address.
Methods: Publications related to HIV-1 DRMinVs from 1999 to 2024 were searched on the Web of Science Core Collection database. Visual knowledge maps and bibliometric analyses were generated using VOSviewer and Bibliometrix.
Results: In total, 289 publications concerning HIV-1 drug-resistant minority variants were identified from 1999 to 2024, demonstrating a steady increase in publication output over the years. Although developed countries, led by the United States, are the main contributors, 9.57% and 2.48% of the research from the top five publishing countries focus on populations in Africa and other developing countries, respectively. Most contributing institutions are universities and public health organizations, with the University of Washington having the highest publication output. The Journal of Antimicrobial Chemotherapy holds the highest prominence among journals in this domain. The main hotspots include "drug classes," "drug resistance surveillance," "mother-to-child transmission," "treatment outcomes," and "targets of HIV-1 drug resistance testing," And we found several noteworthy shifts in research trends in HIV-1 drug-resistant minority variants studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.
Conclusions: This is the first bibliometric analysis of publications related to HIV-1 DRMinVs from 1999 to 2024. We analyzed the key research contributions across countries, institutions and journals. Based on keyword co-occurrence and cluster analysis, we identified several noteworthy shifts in research trends in HIV-1 DRMinVs studies, including changes in drug resistance testing technologies, the primary study population, and drug classes.
期刊介绍:
AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered